[
1. Lammle B, Kremer Hovinga A and Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost. 2005; 3: 1663-75.10.1111/j.1538-7836.2005.01425.x16102032
]Search in Google Scholar
[
2. Gasser C, Gautier E, Steck A, et al. Haemolytischuremische syndrome. Schweiz Med Wochenschr. 1955; 85: 905-9.
]Search in Google Scholar
[
3. Karmali MA, Petric M, Lim C, et al. The association between idiopatic hemolytic-uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis. 1985; 151: 775-82.10.1093/infdis/151.5.7753886804
]Search in Google Scholar
[
4. Siegler RL. The hemolytic-uremic syndrome. Pediatr Clin North Am. 1995; 42: 1505-29.10.1016/S0031-3955(16)40096-98614598
]Search in Google Scholar
[
5. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002; 347: 589-600.10.1056/NEJMra02052812192020
]Search in Google Scholar
[
6. Lowe E, Werner E. Thrombotic thrombocitopenic purpura and hemolytic-uremic syndrome in children and adolescents. Sem Thromb Haem. 2005; 31: 717-29.10.1055/s-2005-92547816388423
]Search in Google Scholar
[
7. Nolasco L, Turner N, Bernardo A, et al. Hemolytic-uremic syndrome-associated Shiga toxins promote endothelial- cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood. 2005; 106: 4199-209.10.1182/blood-2005-05-2111189523616131569
]Search in Google Scholar
[
8. Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001; 98: 2730-5.10.1182/blood.V98.9.2730
]Search in Google Scholar
[
9. Richards A, Kemp EJ, Liscewiski MK, et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad SCI USA. 2003; 100: 12966-71.10.1073/pnas.213549710024072814566051
]Search in Google Scholar
[
10. Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH and IF mutations on clinical presentation, response to treatment and outcome. Blood. 2006. E. Print.10.1182/blood-2005-10-007252189587416621965
]Search in Google Scholar
[
11. Waiser J, Budde K, Rudolph B, et al. De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection. Am J Kidney Dis. 1999; 34: 556-9.10.1016/S0272-6386(99)70085-5
]Search in Google Scholar
[
12. Artz MA, Steenbergen EJ, Hoitsma AJ, Monnens LA, Wetzels JF. Renal transplantation in patients with hemolytic- uremic syndrome: high rate of recurrence and increased incidence of acute rejections. Transplantation. 2003; 76: 821-6.10.1097/01.TP.0000085083.74065.1B14501861
]Search in Google Scholar
[
13. Walter RB, Joerger M, Pestalozzi BC. Gemcitabine-associated hemolytic-uremic syndrome. Am J Kidney Dis. 2002; 40: E16.10.1053/ajkd.2002.3575812324937
]Search in Google Scholar
[
14. Kiyakim A, Ozer C, Yildiz A, at al. Development of transplant renal artery thrombosis and signs of haemolytic- uremic syndrome following the change from cyclosporin to tacrolimus in a renal transplant patient. Nephrol Dial Transplant. 2004; 19: 2653-6.10.1093/ndt/gfh37515388824
]Search in Google Scholar
[
15. Tsai HM: The molecular biology of thrombotic microangiopathy. Kidney Int. 2006; 70:16-23.10.1038/sj.ki.5001535249700116760911
]Search in Google Scholar
[
16. George JN, Nester CM:Syndromes of thrombotic microangiopathy. N Engl J Med. 2014; 371: 654-66610.1056/NEJMra131235325119611
]Search in Google Scholar
[
17. Chua JS, Baelde HJ, Zandbergen M, et al. Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy. J Am Soc Nephrol. 2015; 26(9): 2239-47.10.1681/ASN.2014050429455210825573909
]Search in Google Scholar
[
18. Nester CM, Brophy PD. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement- mediated renal diseases. Curr Opin Pediatr. 2013; 25(2): 225-31.10.1097/MOP.0b013e32835df4a323486421
]Search in Google Scholar
[
19. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013; 368(23): 2169-181.10.1056/NEJMoa120898123738544
]Search in Google Scholar
[
20. Nishimura J-I, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Eng J Med. 2014; 370: 632-9.10.1056/NEJMoa131108424521109
]Search in Google Scholar
[
21. Dhakal P, Giri S, Pathak R, Bhatt VR. Eculizumab in transplant-associated thrombotic microangiopathy. Clin Appl Thromb Hemost. 2015; 23(2): 175-180.10.1177/107602961559943926259912
]Search in Google Scholar
[
22. Vasu S, Wu H, Satoskar A, et al. Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. Bone Marrow Transplant. 2016; 51(9): 1241-124410.1038/bmt.2016.8727064689
]Search in Google Scholar
[
23. Ardissino G, Possenti I, Tel F, Testa S, Salardi S, Ladisa V. Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis. 2015; 66(1): 172-17310.1053/j.ajkd.2015.04.01026111906
]Search in Google Scholar
[
24. Wig S, Chan M, Thachil J, Bruce I, Barnes T. A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor. Rheumatology (Oxford). 2016; 55(2): 382-38410.1093/rheumatology/kev37126472567
]Search in Google Scholar
[
25. Deford CC, Reese JA. Schwartz LH, et al, Multiple major morbidities and increased mortality during long term follow-up after recovery from thrombic thrombocytopenic purpura. Blood. 2013; 122: 2023-910.1182/blood-2013-04-496752377854623838348
]Search in Google Scholar
[
26. Dejan Petrovic, Petar Canovic, Zeljko Mijailovic, Biljana Popovska Jovicic, Sasa Jacovic. Hemolitičko uremijski sindrom: etiopatogeneza, dijagnostika i osnovni principi lečenja. Med J (Krag). 2015; 49(2): 59-65.
]Search in Google Scholar
[
27. Jokiranta TS. HUS and atypical HUS. Blood. 2017; 129(21): 2847-56.10.1182/blood-2016-11-709865544556728416508
]Search in Google Scholar
